The aim of the API-CAT trial was to assess whether the lower dose of apixaban was comparable to the full dose in preventing VTE recurrence in patients with active cancer who had completed at least ...

The Phase III API-CAT trial found that extended anticoagulant therapy with reduced-dose Eliquis (apixaban) was noninferior to the full-dose regimen in preventing recurrent venous thromboembolism in ...

It has a plasma elimination half-life of 12 hours and has been ... without the need for anticoagulation monitoring or dosage adjustment. Apixaban has multiple elimination pathways, and its ...

Medscape Medical News, March 31, 2025 ACC 2025 Low-Dose Apixaban Best for Long-Term Use in Cancer Just as effective as the high dose, low-dose apixaban prevents long-term recurrent venous ...

Visit us on Facebook. Opens in a new tab or window Visit us on X. Opens in a new tab or window Visit us on Instagram. Opens in a new tab or window Visit us on LinkedIn. Opens in a new tab or ...

Stay up-to-date with the latest and best audio content from CBC Listen delivered to your inbox every two weeks.

Antidote medications can stop the effects of warfarin, dabigatran, apixaban, and rivaroxaban ... you closely to make sure you’re on the right dosage and to minimize the risks of complications.